Our pharmaceuticals business provides a wide range of pharmaceuticals and other health care–related products such as diagnostic reagents and liquid diets. As a specialized, R&D-centered international operation, the development of new drugs is advanced to offer innovative and unique therapeutic solutions in the fields of orthopedics, urology, the central nervous system, the immune system, and the circulatory system.
Our medical devices-related business is advancing both the development of new products and the widespread adoption of novel therapeutic technology as a world leader in blood purification systems, including separation and adsorption devices for therapeutic apheresis, artificial kidneys, Sepacell™ leukocyte reduction filters, and Planova™ virus removal filters.
Our critical care business is based on world-leading resuscitation technology. Through our ZOLL family of products, we offer a comprehensive product portfolio that includes professional defibrillators and automated external defibrillators (AEDs), as well as the world’s only wearable defibrillator, an automated cardiopulmonary resuscitation (CPR) device, and a highly efficient intravascular system for managing the core temperature of critically ill patients who require therapeutic cooling or warming.
Operations throughout this business sector are focused on making a contribution to progress in medical therapy by advancing leading-edge technology in new combinations and addressing unmet medical needs for people around the world.
Since the development of Leucomycin™ in 1954, the first antibiotic originating in Japan, Asahi Kasei Pharma has advanced the development of many innovative new drugs. Pharmaceuticals from Asahi Kasei Pharma include Elcitonin™ for treatment of osteoporosis pain, a market leader which is highly recognized for its superior safety and effectiveness. Other notable products are the Flivas™ agent for treatment of benign prostatic hyperplasia and the Toledomin™ antidepressant—Japan’s first serotonin-noradrenalin reuptake inhibitor (SNRI)—and the Recomodulin™ anticoagulant for treatment of disseminated intravascular coagulation—the world’s first thrombomodulin agent produced through genetic engineering. A recent addition to our core product lineup in the field of orthopedics, Teribone™ for osteoporosis is a human parathyroid hormone preparation that facilitates bone formation.
Our diagnostic reagents and assay kits utilize enzyme technology to support health maintenance. The Lucica™ GA-L assay kit is used to measure glycated albumin, newly recognized as an effective indicator for the management of diabetes. The Lucica™ MI assay kit is used to measure myoinositol concentration in urinary samples as a simple and effective screening test for diabetes.
We manufacture a wide range of nutrition-fortified products required at medical institutions and nursing care facilities, as well as for convalescence at home. These include enriched liquid diet, viscosity-adjusted liquid diet, and nutrition-fortified gelatin for elderly persons who cannot take ordinary meals and as nutritional supplement for patients recovering from surgery.
Our dialyzers (artificial kidneys) are developed based on the Asahi Kasei core technology of hollow-fiber membrane separation. Our polysulfone-membrane dialyzers feature superior biocompatibility and permeability, and we hold the No. 1 Japanese share and the No. 2 global share for dialyzers. With distribution extending to more than 70 countries and growing, we continue to help more diabetes patients around the world enjoy a better quality of life.
Our innovative therapeutic apheresis devices enable new possibilities for the treatment of autoimmune and intractable diseases for which drugs are ineffective or unsuitable. Therapeutic apheresis is used to treat a wide range of intractable diseases such as neurological diseases, ulcerative colitis, and hepatic insufficiency. Blood is drawn from a patient and circulated through the device which removes pathogenic substances by separation or adsorption; the treated blood is then returned to the patient. We are the world’s leading producer of devices and systems for therapeutic apheresis, based on our core technologies of membrane separation and selective adsorption.
We manufacture a range of filters and equipment for the production of biotherapeutics and plasma derivatives. Our Planova™ virus removal filters contribute to enhanced safety in the production of plasma derivatives and biopharmaceuticals throughout the world.
We are the world’s leading manufacturer of filters for reduction of leukocytes from blood components for transfusion. By adsorbing leukocytes in an ultrafine fiber membrane, Sepacell™ leukocyte reduction filters help to prevent adverse reactions to blood transfusion such as headache, chills, or fever.
Our clinically advanced defibrillators are used in hospitals and by emergency medical services teams to treat victims of sudden cardiac arrest, while our automated external defibrillators (AEDs) can be found in schools, health clubs, businesses, and many other locations. Not every patient will need a defibrillating shock, but virtually all will require cardiopulmonary resuscitation (CPR), so all ZOLL AEDs and nearly every professional defibrillator we build have Real CPR Help™, real-time audiovisual feedback to help rescuers reach the proper depth and rate of chest compressions. Our revolutionary AutoPulse™ Non-invasive Cardiac Support Pump provides high-quality mechanical chest compressions that move more blood more consistently than is possible with manual compressions.
Our LifeVest™ Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a physician time to assess the patient’s long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, enabling patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA.
We know that controlling a patient’s temperature is fundamental to survival in many critically ill and surgical patients. ZOLL’s Intravascular Temperature Management (IVTM™) system uses special catheters to cool and warm from the inside out. IVTM offers superior clinical efficiency over external methods in reaching and maintaining target temperature, enabling nursing staff to manage the core body temperature of patients easily and effortlessly.
We offer a comprehensive set of pre-hospital and hospital data management systems. Fire and emergency medical services personnel use the ZOLL RescueNet™ suite of software to manage nearly every aspect of their operations, from dispatching and tracking emergency vehicles to transmitting critical patient data from the back of the ambulance to the hospital. Then once the call is over, our software simplifies billing and collections.
ZOLL develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies.